Letters to the editor
2004; Wiley; Volume: 21; Issue: 1 Linguagem: Inglês
10.1002/pdi.575
ISSN2047-2900
Autores Tópico(s)Metabolism, Diabetes, and Cancer
ResumoThe subject of rosiglitazone as adjunctive therapy when patients with type 2 diabetes have reached the state of secondary oral drug failure is of interest to all diabetologists. We therefore read with great expectation the report by Byrne et al.1 in your March 2003 issue. Although the primary aim was to investigate the indication for use of rosiglitazone according to the NICE guidelines, clinical outcome data were reported. Our clinic has ample experience with this drug and our data, in the short term, run somewhat parallel to the results presented by Byrne et al. However, side effects appear early on in the treatment and, as follow-up duration lengthens, cases of drug failure become apparent. Our data were presented at the 18th International Diabetes Federation Congress in Paris.2 In Byrne et al.'s communication, the duration of follow-up could only be guessed as lasting from somewhere between the dates of intake and the date of submission of the article. Another important element missing from the report was the rate of drop-out, either due to lack of clinical effect or to side effects, which is rather considerable after two years (as in our clinic). Therefore the data are less enlightening than was expected. E Kisch MD*, * Endocrinologist, Maccabi Diabetes Clinic, Tel-Aviv/Jaffa, Israel
Referência(s)